102 related articles for article (PubMed ID: 22987290)
1. Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus.
Han SE; Kim MG; Lee S; Cho HJ; Byun Y; Kim S; Kim YB; Choi Y; Oh YK
J Appl Toxicol; 2013 Dec; 33(12):1474-83. PubMed ID: 22987290
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.
Cho H; Lee HJ; Heo YK; Cho Y; Gwon YD; Kim MG; Park KH; Oh YK; Kim YB
PLoS One; 2014; 9(4):e95961. PubMed ID: 24759938
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.
Lee HJ; Hur YK; Cho YD; Kim MG; Lee HT; Oh YK; Kim YB
PLoS One; 2012; 7(11):e50296. PubMed ID: 23209698
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.
Lee HJ; Park N; Cho HJ; Yoon JK; Van ND; Oh YK; Kim YB
Vaccine; 2010 Feb; 28(6):1613-9. PubMed ID: 19961961
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.
Lee HJ; Cho H; Kim MG; Heo YK; Cho Y; Gwon YD; Park KH; Jin H; Kim J; Oh YK; Kim YB
PLoS One; 2015; 10(3):e0119408. PubMed ID: 25789464
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus vector.
Cho HJ; Lee S; Im S; Kim MG; Lee J; Lee HJ; Lee KH; Kim S; Kim YB; Oh YK
Pharm Res; 2012 Feb; 29(2):585-93. PubMed ID: 21948385
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.
Lee HJ; Yoon JK; Heo Y; Cho H; Cho Y; Gwon Y; Kim KC; Choi J; Lee JS; Oh YK; Kim YB
J Microbiol; 2015 Jun; 53(6):415-20. PubMed ID: 26025174
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.
Choi JY; Gwon YD; Kim JK; Cho YD; Heo YK; Cho HS; Choi TJ; Poo HR; Oh YK; Kim YB
PLoS One; 2013; 8(11):e80762. PubMed ID: 24260476
[TBL] [Abstract][Full Text] [Related]
9. Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvant.
Choi HJ; Gwon YD; Jang Y; Cho Y; Heo YK; Lee HJ; Kim KC; Choi J; Lee JB; Kim YB
PLoS One; 2015; 10(6):e0129761. PubMed ID: 26090848
[TBL] [Abstract][Full Text] [Related]
10. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
11. [Production of HPV 16 major capsid protein L1 with baculovirus expression system].
Zheng B; Wang J; Jiang H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):314-6. PubMed ID: 11986713
[TBL] [Abstract][Full Text] [Related]
12. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
Yan X; Wang D; Liang F; Fu L; Guo C
Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
[TBL] [Abstract][Full Text] [Related]
13. [Immune response induced by vaccination with pseudotyped rAAV1 expressing HPV16 L1 protein].
Zhou YB; Li ZL; Zhou L; Sheng W; Ma HT; Zeng Y
Bing Du Xue Bao; 2008 Jul; 24(4):300-4. PubMed ID: 18780634
[TBL] [Abstract][Full Text] [Related]
14. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva.
Millán AF; Gómez-Sebastián S; Nuñez MC; Veramendi J; Escribano JM
Protein Expr Purif; 2010 Nov; 74(1):1-8. PubMed ID: 20600940
[No Abstract] [Full Text] [Related]
16. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
17. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice.
Fan H; Pan Y; Fang L; Wang D; Wang S; Jiang Y; Chen H; Xiao S
J Virol Methods; 2008 Jun; 150(1-2):21-6. PubMed ID: 18394722
[TBL] [Abstract][Full Text] [Related]
18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
[TBL] [Abstract][Full Text] [Related]
20. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
